Publication

Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study

Related publications (53)

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Progestins used for hormonal contraception in Switzerland: study of their effects on the breast epithelium

Marie Shamseddin

Breast cancer is the most commonly diagnosed cancer and the most common cause of cancer death among women. Hormones have been shown to have a key role in breast development and carcinogenesis. Repeated activation of progesterone receptor (PR) signaling as ...

EPFL2018

, ,

Immunohistochemistry (IHC) is one of the main techniques currently used in the clinics for biomarker characterization. It consists in colorimetric labeling with specific antibodies followed by microscopy analysis. The results are then used for diagnosis an ...

SPIE-INT SOC OPTICAL ENGINEERING2018

Microfluidic-assisted chromogenic in situ hybridization (MA-CISH) for fast and accurate breast cancer diagnosis

Martinus Gijs, Raphaël Etienne Jean Trouillon, Huu Tuan Nguyen, Léa Suzanne Bernier

Chromogenic in situ hybridization (CISH) is a common technique that is used for human epidermal growth factor receptor 2 (HER2) assessment in breast cancer diagnosis. CISH is based on the enzymatic amplification of DNA markers, generating a colorimetric im ...

Elsevier2017

Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer

Martinus Gijs, Raphaël Etienne Jean Trouillon, Maryse Fiche, Huu Tuan Nguyen, Seiya Matsuoka

Fluorescence in situ hybridization (FISH) is one of the recommended techniques for human epidermal growth factor receptor 2 (HER2) status assessment on cancer tissues. Here we develop microfluidics-assisted FISH (MA-FISH), in which hybridization of the FIS ...

Nature Publishing Group2017

A novel method for sensitive microRNA detection: Electropolymerization based doping

Tugba Kilic

In the proposed study, for the first time, sensitive electrochemical detection of a breast cancer biomarker microRNA (miRNA), mir-21 was achieved via electropolymerized polypyrrole (PPy) modified pencil graphite electrodes (PPy/PGE). The detection of hybri ...

Elsevier Advanced Technology2017

, , , ,

Cancer diagnosis and personalized cancer treatment are heavily based on the visual assessment of immunohistochemically-stained tissue specimens. The precision of this assessment depends critically on the quality of immunostaining, which is governed by a nu ...

2017

, , , ,

Chromogenic immunohistochemistry (IHC) is omnipresent in cancer diagnosis, but has also been criticized for its technical limit in quantifying the level of protein expression on tissue sections, thus potentially masking clinically relevant data. Shifting f ...

Nature Publishing Group2016

The development of microfluidics has led to significant improvements in many areas of in vitro diagnostics. This thesis proposes the use of microfluidic device technology in the field of anatomic pathology, leading to faster and more accurate tissue-based ...

EPFL2016

FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ENHANCEMENT USING MICROFLUIDIC FLOW FOR AN ACCURATE, FAST AND ECONOMICAL ASSESSMENT OF HER2 STATUS IN BREAST CANCER

Martinus Gijs, Raphaël Etienne Jean Trouillon, Maryse Fiche, Huu Tuan Nguyen, Seiya Matsuoka

The fluorescence in situ hybridization (FISH) is the gold standard in human epidermal growth factor receptor 2 (HER2) status assessment in breast cancer. The dissemination of the technique is impeded by the cost of reagents and long experimental time. For ...

RCS Publising2016

Breast cancer is the most common life-threatening malignancy in women of most developed countries today, with approximately 200,000 new cases diagnosed every year. About 30% of these cases progress to metastatic disease and death. Considering that one-thir ...

EPFL2016